The serine protease thrombin, a naturally derived enzyme, plays a key role in hemostasis by
converting fibrinogen to fibrin and activating coagulation factor XIII whereby the fibrin clot is …

Bypassing agents are presently the standard of care for the treatment of bleeding episodes
in patients with hemophilia and high‐titer inhibitors and are also used for bleed prevention …

Background Freezing is promising for extended platelet (PLT) storage for transfusion. 6%
DMSO cryopreserved PLTs (CPPs) are currently in clinical development. CPPs contain …

Despite the numerous therapeutic options to treat bleeding or thrombosis, a comprehensive
quantitative mechanistic understanding of the effects of these and potential novel therapies …

Recombinant activated factor VII (rFVIIa) is a bypassing agent widely used both in the
treatment and prevention of hemorrhagic complications due to hemophilia with inhibitor. In …

The prophylactic treatment of haemophilia B and the management of haemophilia A or B
with inhibitors demand frequent administrations of coagulation factors due to the suboptimal …

Thrombotic events (TEs) are rare serious complications following administration of
hyperimmune globulin (HIG) products. Our retrospective claims‐based study assessed …

Haemophilia patients with inhibitors require bypassing agents (BPA) like activated
prothrombin complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa) to …

Introduction Haemophilia A or B patients with inhibitors have been treated with FVII a‐
containing bypassing agents for over 20 years. However, due to uncertainty regarding dose …

The aim of this study was to evaluate the capability of thromboelastometry (ROTEM) and
thrombin generation assay (TGA) to monitor the treatment response of bypassing agent …